R Street Policy Analysis: 7-OH Bans Risk Unintended Harms While Research Evidence Remains Limited

Why it matters

Policy think tank cautions that rapid 7-OH scheduling without robust evidence could drive users to illicit markets, increase stigma, and hinder clinical research—offering evidence-based critique of prohibition-focused approaches.

The big picture

As of April 19, 2026, at least five states have banned 7-OH and several more are considering federal Schedule I placement. R Street's analysis argues that while bans are well-intentioned, they follow a prohibition-first pattern that historically has created unintended consequences: driving users away from regulated products to illicit markets, increasing stigma that discourages treatment-seeking, and restricting research that could reveal benefits or guide safer use. The institute advocates for regulation aligned with evidence rather than blanket prohibition.

Key findings

• ['At least 5 states have now banned 7-OH as of April 2026; Congress considering Schedule I placement', '7-OH is 5-50 times more potent than mitragynine but occurs naturally in trace amounts (0.1% or less)', 'Both mitragynine and 7-OH are partial mu-receptor agonists with ceiling effect on respiratory depression (unlike full agonists)', 'Kratom used for centuries in SE Asia with few negative effects; recent US 7-OH products are novel concentrated forms', 'Majority of overdose deaths involve polypharmacy (other drugs present); pure 7-OH fatalities rare']

What they say

R Street analysis: 'While these policies are often well-intended, they represent a reactive approach that oversimplifies a complex issue. Across substances, prohibition and even excessive restriction come with dangers of their own, driving people away from regulated options to illicit markets and unregulated products.'

Bottom line

Policy experts warn that rapid 7-OH bans without evidence-based regulation could mirror past prohibition failures by driving users to illicit markets and hindering research.